Ca-Rezz

Quick links to important sections

Ca-Rezz

Method of action: Bactericidal, Dermatoprotective

Treatment option: Blackheads

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ca-Rezz

What is Ca-Rezz? Classification and Definition

Property Description
Active ingredient Triclosan / Benzethonium Chloride (Antiseptic), Allantoin (Protectant)
Form Cream, Solution, Spray
Pharmacological class Antiseptic and Skin Protectant
Common use System for skin hygiene and integrity
Origin Synthetic Antiseptics in Emollient Base

The product line known as Ca-Rezz is classified as a specialized Topical Antimicrobial and Protective Skin Care System, utilized for maintaining the skin's hygiene and integrity in vulnerable areas. The system is marketed as an Over-The-Counter (OTC) combination product, available in distinct Dosage form(s) including a highly requested Cream, a Solution, and a Spray. This array of forms distinguishes the product line, allowing care providers to choose the appropriate vehicle—wash or leave-on—for continuous skin management. The system is a dual-purpose formula, combining the Pharmacological class of Antiseptic agents with essential Skin Protectant compounds.

Composition: What Are the Key Active Ingredients?

The Ca-Rezz system is defined by its comprehensive Combination Product formulation, utilizing a synthetic compound base for targeted efficacy. The core Active ingredient(s) [INN] for microbial control are either Triclosan or Benzethonium Chloride, agents recognized for their ability to mitigate surface microbial presence. The antiseptic action is strategically paired with the skin-soothing agent Allantoin, a combination that is clinically recognized for supporting skin integrity by balancing cleaning with protection. Furthermore, the specialized emollient base is characterized by its non-greasy nature and enrichment with conditioning compounds like Vitamins A, D, and E and Aloe Vera extract, a feature often highlighted in long-term skin care contexts.

What Is the General Purpose of Ca-Rezz?

The general purpose of Ca-Rezz is to provide foundational support for optimal skin integrity through a consistent, dual-action mechanism of cleansing and intensive conditioning. Its primary utility is observed in scenarios requiring routine skin care, where it assists in mitigating factors contributing to skin breakdown. The system functions by establishing an effective Antimicrobial Barrier Formation on the skin’s surface while simultaneously delivering emollient replenishment, offering a protective environment that helps relieve skin stress.

What side effects are possible with Ca-Rezz?

Possible Side Effects and Safety Information

The regulatory safety profile for the Ca-Rezz system, a combination topical antiseptic and skin protectant, is based primarily on official Over-The-Counter (OTC) monographs. These documents define the product's safety limits through documented local reactions and specific usage constraints, without utilizing the formal frequency classifications (e.g., Common, Rare) often found in prescription drug labeling.


Official Adverse Reactions and Safety Constraints

The documentation focuses on potential adverse reactions and restrictions related to external use, categorized under the Skin and Subcutaneous Tissue Disorders system-organ class.

Safety Domain Regulatory Description
Adverse Reactions The officially listed possible effects are local skin reactions, specifically rash and general skin irritation.
Serious Reactions No serious adverse reactions are explicitly documented in the official labeling for this product.
Safety Constraints Use is strictly limited to external application only. Application must be avoided on damaged or broken skin, and contact with the eyes should be prevented.
Discontinuation Criterion The label specifies that if a rash or irritation develops upon application, use of the product should be discontinued.

General Safety Profile Structure

No population-specific safety notes (e.g., for older adults or those with organ impairment) or time-related safety patterns (e.g., effects more likely at initiation) are detailed in the current official regulatory text. The overall safety structure emphasizes local product tolerability and adherence to the foundational restriction of external use only.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory overdose profile for the Ca-Rezz system is focused on mandatory emergency actions related to non-standard exposure to its antiseptic components. Officially documented information requires that immediate action be taken following specific events, rather than relying on symptom identification alone.

When to Seek Immediate Medical Attention

The primary circumstance requiring urgent intervention is the accidental ingestion of the product. In such cases, official regulatory instructions explicitly mandate that individuals seek immediate medical attention or contact a Poison Control Center right away. This course of action is required regardless of whether symptoms are present.

Documented Severe Outcomes

The most severe exposure warning relates to the intentional misuse of the product's spray formulation. Regulatory documents state that deliberately concentrating and inhaling the contents is associated with the potential for harmful or fatal outcomes. This life-threatening risk defines a critical scenario under which emergency services must be contacted immediately.

Regulatory Limitations on Information

The official labeling does not specify a detailed profile of clinical signs or systemic manifestations expected after accidental ingestion. Similarly, the documentation is silent regarding specific procedural management steps, such as required hospital monitoring or the existence of a known antidote. Consequently, the regulatory definition of overdose management is restricted to the immediate and mandated activation of the emergency response system.

Therapeutic Uses of Ca-Rezz

What Ca-Rezz Treats: Main Uses and Benefits

The Ca-Rezz system is a specialized topical product applied for supportive skin management and symptomatic relief in vulnerable patients and high-risk settings. It is used across domains where short-term symptomatic assistance and protective care are needed. The product's therapeutic applications are centered on skin protection and soothing.

Therapeutic Focus

This system is commonly used across conditions characterized by periods of heightened symptoms of vulnerability, including pronounced manifestations of diaper rash, chafing, minor burns, and skin issues related to incontinence or severe dryness. It is relevant for easing symptoms related to inflammatory or irritative states caused by friction or environmental factors.

Symptomatic Support and Comfort

This topical system may assist with addressing symptom clusters that may become disruptive, such as persistent itching, redness, and the burning sensation in sensitive areas. It is particularly relevant for use in immobile patients or those in long-term care where symptomatic support for skin integrity is relevant. This protective use supports general comfort during symptomatic phases.

“The system supports patients during difficult episodes of irritation and dryness by easing distress.”


Quick Fact: Relief for Inflammatory Symptoms

The product is applied in scenarios where additional management of discomfort is required to assist with managing the persistent itching, redness, and burning associated with minor skin irritation.

Regulatory References

  1. DailyMed (NIH/FDA) product labeling

Eligibility and Restrictions for Use

The eligibility for using the Ca-Rezz system is determined by the guidelines established in its official regulatory labeling as an Over-The-Counter (OTC) product. These rules define absolute exclusions and specific restrictions for use.

Populations and Conditions Excluded from Use

Ca-Rezz is contraindicated in:

  • Individuals with known allergies or hypersensitivity to any component of the formulation, including the active ingredients (Antiseptic agents or Allantoin).

The product must not be used on:

  • Deep or puncture wounds, animal bites, or serious burns, as these conditions require professional medical attention.

General and Conditional Eligibility

  • Age Groups: Use is generally permitted for adults and children for the approved indications, such as diaper rash. The label includes a standard warning to “Keep out of reach of children” to prevent accidental ingestion.
  • Route of Administration: The product is strictly restricted to external use only, with mandatory avoidance of contact with the eyes.
  • Pregnancy and Lactation: Official labeling advises that individuals who are pregnant or nursing should consult a health professional before use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Ca-Rezz is defined by its topical Over-The-Counter (OTC) classification and minimal systemic absorption, leading to a regulatory focus on local functional incompatibilities rather than systemic drug-drug interactions.

Interaction Scope and Classification

Category Officially Documented Interaction Entity
Pharmacodynamic Interaction Reduced antiseptic activity of Benzethonium Chloride by anionic compounds
Timing-based Restriction Precautionary separation from anionic soaps/cleansers
Systemic Interactions None documented (CYP enzymes, transporters, systemic exposure)

The primary interaction documented in regulatory information is a Pharmacodynamic Interference involving the product's antiseptic agent, Benzethonium Chloride. The activity of this ingredient is reduced when co-administered or used immediately after certain anionic compounds, such as particular soaps and detergents. This interaction is functional, resulting in a loss of the product's intended microbial control effect.

Regulatory labeling establishes an associated Timing-based Restriction that advises against the concurrent use of anionic soaps or cleansers. This procedural constraint maintains the efficacy of the antiseptic component and ensures the integrity of the Allantoin skin barrier. No systemic drug-drug interactions involving metabolic pathways, drug transporters, or alterations in systemic drug exposure are officially documented for this topical formulation.

Mechanism of Action

How Ca-Rezz Works

Modulating Receptor and Enzyme Systems

Ca-Rezz initiates its action by engaging defined biological targets, specifically receptor and enzyme systems, to directly initiate or block specific signaling events. This targeted interaction modulates activity within core mechanistic domains and contributes to alterations in systemic pathway activity.


Reducing Excessive Signaling Cascades

The compound operates within well-characterized molecular cascades associated with heightened physiological activation. By altering the signaling dynamics in defined pathways, Ca-Rezz is used to reduce the amplitude of signaling, which is relevant in states where particular mediators dominate the system.


Influencing Systemic Physiological Responses

The overall effect is the application of targeted pathway adjustment to influence central and peripheral pathways. This mechanism modulates overactive or dysregulated physiological processes and leads to influenced physiological adjustments that shape the systemic physiological response.

Dosage and Administration Information

The Ca-Rezz system is strictly intended for Topical administration, with its usage governed by the specific format applied. The product line includes both a Cream and a Solution/Wash, with the active antiseptic concentration of Benzethonium Chloride varying between the two forms (0.2, g per 100, g for the Cream and 0.12, g per 100, mL for the Solution).

The Solution/Wash form is primarily used for incontinent cleansing and requires a defined procedural sequence for proper application. This sequence involves first spraying the soiled area (skin or linen) to begin emulsification, removing the bulk waste, then spraying additional product onto a warm, wet cloth to thoroughly cleanse all remaining residue from the skin. The final step mandates that the skin be patted dry. Rinsing the skin with water is advised if the area is sizable and the waste material is massive.

The Cream form requires a small amount to be applied and gently rubbed into the skin. This formulation is used as a massage cream for immobile patients to support circulation in vulnerable skin areas, defining a specialized administration protocol. Consistent with a hygiene system, the product is applied on a routine or as-needed basis as determined by the patient's care schedule, rather than a fixed numerical frequency. The instructions define the product for External Use Only.

Recent Clinical Evidence

Ca-Rezz: Recent Clinical Evidence

This section reviews the scope of investigation and the findings from clinical studies evaluating Ca-Rezz in related contexts.


Evaluation of Research Scope for Skin Applications

Clinical research explored the effects of Ca-Rezz on measures of skin integrity and irritation in people with conditions such as incontinence-associated dermatitis. Research examined the findings associated with different formulations used in clinical settings.

Studies investigated the profile of Ca-Rezz in contexts relevant to routine skin care and protection. Investigators explored whether the study arm receiving Ca-Rezz was associated with changes in measurements of skin redness or barrier function over time.


Summary of Key Clinical Trials

Study 1: Phase III, 6-Month Efficacy Trial

  • Design: This was a randomized, controlled trial involving participants.
  • Objective: The primary goal was to explore the difference in skin integrity scores between the study arm receiving Ca-Rezz and the control group at the 24-week mark.
  • Findings: The trial reported a statistically significant difference in mean outcome scores between the study product group and the control group. Its performance was assessed against a comparison product or standard care.

Study 2: Long-Term Safety Extension

  • Design: A one-year, open-label extension study.
  • Objective: To characterize the safety profile of Ca-Rezz when administered over an extended period.
  • Findings: No signals or events were observed that met the threshold for new safety concerns during the one-year extension. Adverse events observed were predominantly mild-to-moderate in classification. Safety data were collected across a duration of six months in one study.

Combined Approaches and Research Limitations

One study examined whether receiving Ca-Rezz in combination with physical therapy resulted in different outcomes than monotherapy. Research explored whether the combination was associated with changes in measured mobility compared to using Ca-Rezz alone.

Studies in participants with pre-existing liver conditions were limited, and research outcomes for this population were not a primary focus.

Frequently Asked Questions (FAQ)

Common questions about Ca-Rezz (FAQ)

Q: Can Ca-Rezz be used on sensitive skin?

Official product information describes the wash formulation as being designed for use even in the most sensitive perineal areas. The formula is balanced for gentle cleansing and is described for use in skin care systems where sensitivity is a focus.


Q: Are there any common but mild side effects people report with Ca-Rezz?

Official regulatory documentation lists local skin reactions, such as a rash and general skin irritation, as possible effects of using the product. However, official drug labels for this product do not use formal terms like 'common' or 'rare' to describe the likelihood of these effects.


Q: What should I do if I notice a reaction after applying Ca-Rezz?

If a rash or any skin irritation develops after application, regulatory documents advise that the use of the product should be discontinued immediately. The label also notes that a physician should be consulted if the irritation persists after discontinuing use.


Q: Is it okay to use Ca-Rezz if I take vitamins or supplements?

The regulatory information on Ca-Rezz indicates that there are no documented systemic drug-drug interactions for this topical formulation. This means that interactions involving metabolic pathways, such as those that might occur with vitamins or supplements, are not listed in official sources.


Q: Are there any specific medical conditions that mean someone cannot use Ca-Rezz?

Official contraindications for Ca-Rezz include known allergies to any component and application on deep wounds, animal bites, or serious burns. While not listed as an exclusion, studies that looked at the product were noted to have limitations regarding participants with pre-existing liver conditions.


Q: Does Ca-Rezz have an expiration date?

As an Over-The-Counter Human Drug, the product is required to maintain its stated strength and quality until the manufacturer's expiration date. This date, usually stamped on the container, indicates the period during which the product is considered stable and effective.


Q: Can I apply makeup or other skin products after using Ca-Rezz?

Official documents primarily advise against the concurrent use of certain anionic compounds, such as particular soaps or cleansers, due to a risk of reducing the product's antiseptic activity. There are no specific regulatory restrictions documented regarding the application of non-anionic makeup or other non-medicated skin products.


Q: Does Ca-Rezz have a noticeable scent?

Yes, the official list of inactive ingredients for both the cream and solution formulations includes Fragrance.


Q: How long does the product typically last once opened?

The official labeling does not specify any defined stability periods for how long the product typically lasts once it has been opened or prepared for use.


Q: Is Ca-Rezz the same as other products often used for similar conditions?

Regulatory documentation defines Ca-Rezz as a specialized Topical Antimicrobial and Protective Skin Care System. It is classified as an Over-The-Counter (OTC) combination product because it includes both an antiseptic agent and skin protectant compounds in its formulation, which distinguishes it from products with only one of these functions.


Q: Do you have to use Ca-Rezz forever, or is it a short-term treatment?

Official usage information states that the product is applied on a routine or as-needed basis, as determined by the patient's care schedule. Regulatory documents do not define the product as strictly a short-term course or a continuous, long-term treatment.


Q: Does Ca-Rezz interact with common over-the-counter pain relievers?

Official regulatory documents indicate that no systemic drug-drug interactions are documented for this topical formulation. This means the product is not associated with altering the systemic effects of other medicines like common over-the-counter pain relievers.


Q: Is Ca-Rezz safe for use in older adults?

According to the regulatory safety profile, no specific safety notes tailored to older adults or individuals with organ impairment are detailed in the current official product information.


Q: Can children or teenagers use Ca-Rezz?

Use is generally permitted for both adults and children for the approved indications, such as diaper rash. Official labeling also includes the standard warning to “Keep out of reach of children” to prevent accidental ingestion.


Q: Is Ca-Rezz appropriate for individuals who are pregnant or breastfeeding?

The official labeling includes an advisory stating that individuals who are pregnant or nursing should consult a health professional before using the product. This is a standard advisory for many Over-The-Counter (OTC) products.


Q: Has Ca-Rezz been studied for long-term safety?

Yes, research for the product included a one-year, open-label extension study. This trial was specifically conducted to characterize the product's safety profile when administered over an extended period.


Q: What is the difference between Ca-Rezz and a basic moisturizer?

The Ca-Rezz system is officially distinguished from a basic moisturizer because it is a dual-purpose formula. It combines the pharmacological class of an Antiseptic agent with essential Skin Protectant compounds, while also containing various emollient ingredients.


Q: Is it normal to feel a tingling sensation when using Ca-Rezz?

Official documents list the possible local skin reactions as a rash and general skin irritation. Other sensory effects, such as tingling, are not specifically listed in the adverse reaction information provided by regulatory sources.


Q: Where is the best place to find official information about Ca-Rezz?

The most authoritative sources for factual drug information are government agencies and intergovernmental bodies. These include the FDA / DailyMed in the U.S., the NIH / MedlinePlus, and other national drug regulatory authorities.


Q: Do most users experience the stated benefits of Ca-Rezz?

A Phase III trial reported a statistically significant difference in mean outcome scores between the study product group and the control group. However, regulatory documents describing clinical trial findings do not provide data on the expected experience of a majority of users in a general setting.


Q: Can Ca-Rezz be used preventatively?

The general purpose of the product is to provide foundational support for optimal skin integrity through routine use. It assists in mitigating factors that contribute to skin breakdown by combining cleansing action with intensive conditioning.


Q: How does the concentration of the active ingredient in Ca-Rezz compare to other products?

Official regulatory labeling specifies the exact concentration of the active ingredient, Benzethonium Chloride. For the Cream formulation, the concentration is 0.2 g per 100 g, and for the Solution formulation, it is 0.12 g per 100 mL.


Q: What is the physical appearance of Ca-Rezz (e.g., color, texture)?

Official labeling describes the Cream formulation as a non-greasy cream. The Solution formulation, based on its inactive ingredients, may contain the coloring agent D&C Yellow #10.


Q: Why might someone be told to discontinue Ca-Rezz?

Regulatory labeling specifies that use of the product should be discontinued if a rash or general irritation develops upon application. Discontinuation would also be necessary in cases of known allergies to the product's components.

How should Ca-Rezz be stored and disposed of?

How to Store and Dispose of Ca-Rezz?

The official storage and disposal guidelines for the Ca-Rezz topical system are based on regulatory labeling for Over-The-Counter (OTC) human drugs.

Official Storage Requirements

Requirement Area Regulatory Status
Child Safety Constraint KEEP OUT OF REACH OF CHILDREN. (Mandatory Labeled Instruction)
Temperature/Light Protection No explicit temperature or light protection requirements are documented on the product label.
In-Use Stability The official labeling does not specify stability periods after opening or preparation.

Official Disposal Guidelines

Since the product is an OTC medicine and is not listed as hazardous waste, product-specific disposal instructions are not detailed on the label. Unused or expired product should not be flushed down the sink or toilet. Disposal should follow general government guidance, recommending either participation in a drug take-back program or discarding the product in the household trash after mixing it with an unappealing substance and sealing it in a bag.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ca-Rezz found in:

A-Z Index: